<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126917</url>
  </required_header>
  <id_info>
    <org_study_id>ZX002-0901</org_study_id>
    <nct_id>NCT02126917</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)</brief_title>
  <official_title>Single-center, Open-Label, 3-Period Crossover, Phase 1 Study to Evaluate the Pharmacokinetics of Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules 50 mg When Co-Administered With Alcohol in Healthy Subjects Under Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the influence of co-ingestion of alcohol on HC-ER.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the influence of co-ingestion of alcohol on the safety, pharmacokinetics, and
      relative bioavailability of HC-ER 50 mg under fasted conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the rate and extent of absorption of HC-ER 50 mg capsule following co-ingestion of alcohol under fasted conditions.</measure>
    <time_frame>Day 1 through Day 18</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HC-ER + 40% Alcohol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC-ER + 20% Alcohol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC-ER + 0% Alcohol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER + 40% Alcohol</intervention_name>
    <description>HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state</description>
    <arm_group_label>HC-ER + 40% Alcohol</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER + 20% Alcohol</intervention_name>
    <description>HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state</description>
    <arm_group_label>HC-ER + 20% Alcohol</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER + 0% Alcohol</intervention_name>
    <description>HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state</description>
    <arm_group_label>HC-ER + 0% Alcohol</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, ages 21 to 45.

          -  Female, must be of non-childbearing potential.

          -  Non-smokers for at least 3 months or light smokers (less than 10 pack-years).

          -  History of moderate consumption of between 7-21 units of alcohol per week.

          -  Weighed at least 65 kg with a BMI ≥19 and ≤35 kg/m2.

          -  Were medically healthy with no clinically significant abnormalities.

          -  Voluntarily consented to participate in the study.

          -  Were prepared to be compliant with the study procedures.

        Exclusion Criteria:

          -  Women who were pregnant or breastfeeding.

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  History or presence of alcoholism or drug abuse.

          -  Hypersensitivity or idiosyncratic reaction to morphine, hydrocodone (Vicodin) or other
             opioids; naltrexone, naloxone, or other opioid antagonist.

          -  History of no alcohol intake (alcohol-naive) or less than moderate alcohol intake.

          -  History of alcohol intake exceeding the equivalence of 21 units/week or exceeding the
             average of 3 drinks per day.

          -  Surgery of the gastrointestinal tract which would interfere with absorption of the
             study drug.

          -  Taken hepatic enzyme inducing drugs (e.g., Nizoral, Tagamet) within the previous 3
             months.

          -  Taken prescription medications within the previous 14 days or over the counter (OTC)
             medications within the previous 7 days prior to Day 1 Period 1.

          -  Sitting blood pressure was less than 110/45 mmHg at screening.

          -  On a special diet (except for vegetarians who agree to abide by study diet) during the
             28 days prior to the first dose and throughout the study.

          -  Significant blood donation or loss within 56 days prior to first dose of HC-ER.

          -  Plasma donation within 7 days prior to first dose of HC-ER.

          -  Hemoglobin value less than 12.0 g/dL.

          -  Participated in another clinical trial within 28 days prior to first dose of HC-ER.

          -  Positive urine test for drugs of abuse.

          -  Positive test for, or had been treated for hepatitis B, hepatitis C or HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Kissling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zogenix, Inc.</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>April 28, 2014</last_update_submitted>
  <last_update_submitted_qc>April 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Alcohol</keyword>
  <keyword>Hydrocodone Bitartrate</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

